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NOD1 deficiency promotes 
an imbalance of thyroid hormones 
and microbiota homeostasis 
in mice fed high fat diet
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The contribution of the nucleotide‑binding oligomerization domain protein NOD1 to obesity has 
been investigated in mice fed a high fat diet (HFD). Absence of NOD1 accelerates obesity as early 
as 2 weeks after feeding a HFD. The obesity was due to increases in abdominal and inguinal adipose 
tissues. Analysis of the resting energy expenditure showed an impaired function in NOD1‑deficient 
animals, compatible with an alteration in thyroid hormone homeostasis. Interestingly, free thyroidal 
T4 increased in NOD1‑deficient mice fed a HFD and the expression levels of UCP1 in brown adipose 
tissue were significantly lower in NOD1‑deficient mice than in the wild type animals eating a HFD, 
thus contributing to the observed adiposity in NOD1‑deficient mice. Feeding a HFD resulted in an 
alteration of the proinflammatory profile of these animals, with an increase in the infiltration of 
inflammatory cells in the liver and in the white adipose tissue, and an elevation of the circulating 
levels of TNF‑α. In addition, alterations in the gut microbiota in NOD1‑deficient mice correlate with 
increased vulnerability of their ecosystem to the HFD challenge and affect the immune‑metabolic 
phenotype of obese mice. Together, the data are compatible with a protective function of NOD1 
against low‑grade inflammation and obesity under nutritional conditions enriched in saturated lipids. 
Moreover, one of the key players of this early obesity onset is a dysregulation in the metabolism and 
release of thyroid hormones leading to reduced energy expenditure, which represents a new role for 
these hormones in the metabolic actions controlled by NOD1.
Abbreviations
HFD  High fat diets
JNK  C-Jun N-terminal kinase
KO  Knockout
MAPK  Mitogen-activated protein kinase
q(RT)-PCR  Quantitative real-time (RT) polymerase chain reaction
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis
WT  Wild-type
The nucleotide-binding oligomerization domain (NOD) protein NOD1 belongs to the NOD-like receptor (NLR) 
family of pathogen recognition receptors. NOD1 is a cytoplasmic protein that recognizes conserved fragments 
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found in the cell wall of many types of Gram-negative or Gram-positive  bacteria1. NOD1 resides as an inactive 
monomer in the cytoplasm and, upon ligand recognition, a conformational change occurs favoring oligomeri-
zation and recruitment of the serine/threonine-protein kinase 2 (RIPK2) through homotypic CARD–CARD 
 interactions2,3. RIPK2 mediates the recruitment and activation of the serine/threonine kinase TAK1, which is a 
prerequisite for activation of the IκB kinase complex, leading to both the canonical NF-κB and MAPK activa-
tion  pathways4. The bacterial determinants involved in NOD1 activation have not been yet fully elucidated, but 
several studies have demonstrated that the minimal motif γ-d-glutamyl-meso-diaminopimelic acid (iE-DAP), 
present in most bacterial peptidoglycans, is sufficient to fully activate  NOD11,2. Although NLRs and TLRs are 
thought to play partial redundant roles, their expression pattern shows certain specificities that can be evidenced 
in genetically targeted animal models challenged with different  pathogens1,5. NOD1 is widely expressed by a 
variety of cell types, but is significantly represented in epithelia, stromal and endothelial cells, adipocytes and 
in the  thyroid6,7, and to a lesser extent in resting myeloid  cells3,4,8–10. Activation of NOD1 in intestinal epithelial 
cells triggers the production of chemokines and the recruitment of acute inflammatory cells in vivo, playing a 
role in the immune response against pathogenic  microbes4,11,12. Indeed, NOD1 KO mice are more susceptible to 
multiple bacterial pathogens suggesting a specific role for this receptor in the innate defense mechanisms of the 
intestinal epithelium against acute  infections13–16. Moreover, NOD1 also exerts a protective role against chronic 
intestinal inflammatory processes, like colorectal cancer as deduced from NOD1 or RIPK2 deficient mice chal-
lenged with different colonic tumor  inducers13,15–17, proving its role in the maintenance of intestinal homeostasis.
The innate immune system is strongly associated with obesity, insulin resistance, metabolic syndrome and 
 diabetes18. Recent studies suggest that much of this interplay is due to NLR activation, in particular  NOD118–20. 
Moreover, insulin resistance has been associated with both NOD1 and NOD2 activities by eliciting pro-inflam-
matory signaling pathways in adipocyte cell models and in in vivo studies on human adipose  tissue20–23. Indeed, 
it appears that several fatty acids can moderately activate these NLRs leading to a chronic low-grade inflam-
matory  tone15,24. Several studies suggest that the intestinal barrier becomes compromised during HFD feeding, 
resulting in translocation of gut bacterial components into systemic  circulation18. Therefore, intestinal epithelial 
NOD1 may play a protective role in strengthening the gut barrier and restricting this bacterial influx in obesity. 
Accordingly, mice deficient in NOD1 present an exacerbated systemic inflammation under HFD, in addition to 
alterations in the broad metabolic homeostasis of the  animals2,20,24,25. In this work, we have examined the impact 
of a HFD in NOD1 deficient mice compared to wild-type (WT) mice during the early onset of diet-induced 
obesity. Our data show that NOD1 deficient mice fed a HFD for six weeks exhibit an exacerbated increase in 
lipogenesis in the iWAT and eWAT, but this occurs in the absence of an evident insulin resistance phenotype. 
In addition to this, important alterations in thyroid hormone dynamics were observed when comparing WT vs. 
NOD1 KO mice fed a HFD, which probably are involved in the progression to further metabolic dysfunctions. 
The NOD1 deletion also influences the composition of the gut microbiota and the HFD-induced alterations 
associated with a worse metabolic phenotype.
Materials and methods
Materials. Common reagents were from Sigma-Aldrich-Merck (St Louis, MO, USA) or Roche (Darmstadt, 
DE). Murine or human cytokines were obtained from PeproTech (London, UK). Antibodies were from Ambion 
(Austin, TX, USA), Abcam (Cambridge, UK) or Cell Signaling (Danvers, MA, USA). Reagents for electropho-
resis were from Bio-Rad (Hercules, CA, USA). Tissue culture dishes were from Falcon (Lincoln Park, NJ, USA), 
and serum and culture media were from Invitrogen (Life Technologies/Thermo-Fisher, Madrid, ES).
Animal care and tissue preparation. Wild type (WT) and homozygous Nod1−/− (NOD1 KO) mice (both 
in the mixed C57BL/6 and 129/C57BL/6 background), have been previously  described7,26,27. Male NOD1 WT 
or KO were housed under 12 h light/dark cycle and food and water was provided ad libitum (chow diet: CHD; 
2.05% fat, mainly oleic and linoleic acids; SAFE-PANLAB, ES) for 12 weeks. Animals were then maintained in 
CHD or switched to a high-fat diet (HFD; 10.2% hydrogenated coconut fat and 0.75% cholesterol; Ssniff, Soest, 
DE) which was provided ad libitum for six weeks. Treatment with the NOD1 activator iE-DAP was achieved as 
previously  described7. Animals were cared for according to the protocol approved by the Ethical Committee of 
CISC, and in accordance to directive 2010/63/EU of the European Parliament.
Evaluation of animal metabolic profile. Animals under analysis were maintained individually in Phe-
nomaster Metabolic Cages (TSE Systems International Group) from day 33 to day 38 and the evaluation was 
done during day 35–38. Spontaneous physical movement, drink and food intake, respiratory exchange  (O2 and 
 CO2), weight and heat production were monitored as previously  described28.
Evaluation of the glucose tolerance test. Mice underwent a glucose tolerance test (GTT) at the begin-
ning of the HFD and at week 6 of treatment. Animals were fasted overnight and injected with 2 g of glucose per 
kg body weight. Blood glucose was measured with an Accu-Check glucometer (Roche) from the tail vein at 0, 
15, 30, 60 and 120 min. Plasma insulin levels were determined using an ELISA kit (Mercodia, Uppsala, SE) and 
in parallel to the glucose determination (15 min after glucose administration).
Assay of total bile acids (BA). A fluorimetric assay (Sigma-Aldrich) was used to determine total bile 
acids in serum and in liver extracts. The assay is based on the use of 3-hydroxysteroid dehydrogenase that reacts 
with twelve BA, reducing NAD to NADH. Appropriate internal controls were used to ensure the linearity and 
specificity of the reaction.
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1H NMR analysis of liver lipids. HRMAS analysis was run at 4 °C in an 11.7 T Bruker Avance spectrom-
eter at 500.113 MHz, and using 5 kHz spinning rate, following a previously described protocol for  lipids29,30. The 
ex vivo spectra were quantified by using MestReC software (Mestrelab Research, Santiago de Compostela, ES). 
Validation of 1H MR spectra were obtained from different FA standards and data were generated using heuristic 
analysis. Results were expressed as: SFA: saturated fatty acids (FFAA); UFA: Unsaturated FFAA; MUFA: mono-
unsaturated FFAA; PUFA: polyunsaturated FFAA; MCL: medium chain length FFAA; NDB: number of double 
bonds in FFAA; PU/UFA, polyunsaturated/unsaturated fatty acids; saturation index (Sat. Index), as the ratio 
between stearic and oleic acids, reflecting membrane rigidity.
Quantification of myeloid cell populations. Animals were fed as indicated and the presence of myeloid 
cells in the eWAT and liver at 24 h was assessed in a FACSCanto II flow cytometer as previously  described7. The 
adipose tissue (eWAT) was mechanically digested using an enzymatic solution (type II collagenase,  CaCl2 plus 
BSA) for 20 min at 37 °C in a rotational shaker (200 rpm). Leukocyte subsets were defined using FlowJo soft-
ware: neutrophils  (CD45+CD115−Ly6G+), inflammatory monocytes  (CD45+CD115+) and tissue macrophages 
 (CD45+CD115−F4/80+)-population31.
Preparation of total protein cell extracts. Tissues were homogenized as previously described in the 
presence of 1 mM β-mercaptoethanol, detergent (0.5% CHAPS) and protease and phosphatase inhibitor cocktail 
from Sigma. Extracts were centrifuged and protein content was  quantified7.
RNA isolation and analysis. RNA was extracted in TRIzol and processed in a Real-time PCR equipment 
as previously  described7,32. Samples were analyzed in duplicate vs. 36B4. Dio2, Ucp1 and Dio1 were assayed using 
specific Taqman probes (Mm01244861m1 for Ucp1, Mn00515664m1 for Dio2, Mn00839358_m1 for Dio1 (Gene 
expression assays, Applied Biosystems, Foster City, CA). Results were normalized to cyclophilin labelled with 
VIC (Ppia, Mm02342429g1, Applied Biosystems) in the same well. The fold-change in mRNA expression was 
calculated by the  2−ΔΔCt method.
Protein analysis by Western blot. Protein cell extracts were boiled in 250 mM Tris–HCl, pH 6.8; 2% 
SDS, 10% glycerol and 2% β-mercaptoethanol, and equal amounts of protein were separated by SDS-PAGE elec-
trophoresis in 8–10% gels and visualized by ECL chemiluminescence as  described7,32. The antibodies used were 
from Abcam or Cell Signaling.
Thyroid hormones determinations. The concentrations of T3 and T4 were measured after extraction 
and purification from plasma, liver, brown adipose tissue (BAT) and thyroids using specific radioimmunoassays. 
For hormone measurement in thyroids, tissues were homogenized in ethanol, and thyroidal free (F) T4 and T3 
were determined in the dried extracts as  described33.
Deiodinase activities. D2 in BAT and D1 in liver. 125I-T4 and 125I-rT3 were synthetized and purified to 
reduce iodide to less than 1% of the total 125I. D2 activity was assayed as previously  described34,35. D1 activity was 
determined as previously  described36.
Histological analysis and immunostaining. Mouse liver and eWAT tissues were fixed in 4% paraform-
aldehyde in 0.1 M PBS and embedded in paraffin. 5 μm sections of tissue were deparaffinized sections were 
stained with hematoxylin/eosin (HE) or Oil-Red O using standard procedures.
Microbiota analysis. Analysis of gut microbiota. Fecal samples from individual mice from each experi-
mental group (n = 10 for control, n = 8 for NOD1 KO) were collected after 12 weeks on a CHD and then at 
6 weeks after the switch to the HFD and stored in 2 ml cryovials. Samples were immediately frozen in liquid 
nitrogen and maintained at − 80 °C. DNA extraction was done using Fast DNA Stool Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions with several modifications: Fecal samples (ca. 220 mg) were homogenized 
with glass beads in the presence of 1 ml of Inhibitex buffer (Qiagen) using a beadbeater for 2 successive rounds 
for 1 min and then heated to 95 °C for 10 min. DNA was PCR-amplified in triplicate using primers (S-D-Bact-
0341-b-S-17/S-D-Bact-0785-a-A-21) that target the V4–V5 variable regions of the 16S rRNA gene, following a 
previous  protocol37. Samples were tagged with barcodes to allow multiplexing during the sequencing process. 
Sample amplicons were combined and purified using the Illustra GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare) according to the manufacturer’s instructions and combined in equimolar concentrations before 
carrying out sequencing on a MiSeq instrument (Illumina). All raw sequence data has been submitted to ENA-
EMBL Accession # PRJEB33681.
Bioinformatic processing of data was carried out using the software QIIME1 (version 1.9.1)38,  Mothur39, 
and  UPARSE40. Briefly, using QIIME1, paired-end forward and reverse Illumina reads were joined into contigs 
(join_paired_ends.py), barcodes were extracted (extract_barcodes.py), and reads were demultiplexed (split_
libraries_fastq.py). Sequences smaller than 325 bp or containing homopolymers greater than 7 were removed 
using the screen.seqs() command from the software program Mothur. Primers were then removed using trim.
seqs() from Mothur. Using UPARSE, chimeras were removed and reads were clustered at 97% identity into OTUs 
using default settings. An OTU abundance table was generated within the UPARSE pipeline by mapping reads to 
representative sequences for each OTU. Using QIIME, a biom file was created from the OTU table and reads were 
rarefied (single_rarefaction.py) and singletons were removed (filter_otus_from_otu_table.py). A phylogenetic 
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tree was constructed from representative sequences for each OTU, and aligned (align_seqs.py) using  PYNAST41 
and filtered (filter_alignment.py) using default settings. Alpha diversity metrics (Shannon’s, Chao1, observed 
OTUs) were calculated (alpha_diversity.py). Beta diversity analysis was conducted using generalized UniFrac 
(GUniFrac)42. Taxonomy was assigned to representative OTUs (summarize_taxa.py) using UCLUST against the 
Greengenes database (version 13.8).
Statistical analyses of microbiota. The biomarker discovery method LDA Effect Size  (LEfSe43) was employed to 
compare the effect of genotype (WT vs. NOD1 KO groups) under a CHD and HFD diet, as well as examine the 
effects of a HFD after 6 weeks. Comparisons of beta diversity between groups using generalized UniFrac were 
performed by a PERMANOVA with adonis within the GUniFrac package in R.
Statistical analysis. After normality, the statistical analysis was calculated by D’Agostino-Pearson omni-
bus test, either a nonparametric test (Mann–Whitney U test), or a normality test (unpaired Student’s t test with 
Welch’s correction, ordinary 1-way ANOVA) was used as appropriate. Removal of outliers was assessed by the 
ROUT method. Results were considered statistically significant at P < 0.05.
Results
Loss of NOD1 accelerates diet‑induced obesity. WT and NOD1-deficient mice fed standard CHD 
did not show differences in body weight across the lifetime of the animals (not shown). However, after 6 weeks 
on HFD, statistically significant differences in body weight were observed, mainly due to fat accumulation in 
the eWAT, iWAT and BAT (Supplementary Fig.  S1a, Fig.  1a,b), but not in other organs (e.g., liver; Fig.  1b). 
The increase in body weight of NOD1-deficient mice fed HFD was statistically significant after two weeks of 
treatment, having both groups the same tibiae size (Supplementary Fig. S1a,b). Regarding blood lipids, HFD-
fed mice exhibited an increase in total cholesterol (TCHO) due to an elevation in the HDL fraction, but no 
differences were observed in other lipids assayed, including triglycerides (TGA) and non-esterified fatty acids 
(NEFA; Fig. 1c). When animals were analyzed in metabolic cages, NOD1-deficiency in mice fed CHD resulted 
in higher respiratory activity. However, a depressed respiration during the darkness period was observed in 
NOD1-deficient mice vs. the WT counterparts when fed a HFD (Fig. 2a). These metabolic differences included a 
substantial decrease in Resting Energy Expenditure (REE) during darkness and in lesser motion in HFD NOD1 
KO animals, a situation opposite to that observed under CHD (Fig. 2b, and Supplementary Fig. S2), suggesting 
a role for thyroid hormones (a key player in REE) in this differential  response44. However, no significant differ-
ences in body temperature (not shown), and food and beverage intake were observed between WT and NOD1 
KO mice regardless the dietary regimen (Supplementary Fig. S2). To further investigate the mechanisms associ-
ated with the observed body weight gain, the glucose tolerance test was evaluated. No differences in the time-
dependent glucose drop were observed in animals under CHD; however, NOD1 KO mice fed HFD exhibited an 
unexpected improvement in the glucose tolerance test that was not due to differences in plasma insulin levels 
(Fig. 3a,b). These data are compatible with increased GLUT-4 expression from eWAT in NOD1 KO mice, sug-
gesting improved glucose homeostasis (Fig. 3c). Nevertheless, no significant differences in phospho-AKT were 
observed under these conditions (Fig. 3c).
NOD1 deficiency increases white adipocyte lipid content and promotes liver steatosis in 
HFD‑fed mice. Since eWAT seems to be one of the tissues responsible for the increased body weight in 
NOD1 KO mice fed HFD, a histological analysis of this tissue was performed. In agreement with the body weight 
increase of NOD1 KO mice, a very significant enlargement of adipocytes was observed, indicating obesity or at 
least overweight (Fig. 4a). The RNA levels of key adipocyte lipases and lipid metabolism genes were determined 
(Fig. 4b). The phospholipase Pnpla3 (patatin-like phospholipase domain-containing protein 3; Pnpla3), which 
is upregulated by T3 and mediates the hydrolysis of triglycerides in adipocytes playing a role on lipid storage 
 homeostasis45,46, was decreased in NOD1 KO adipose tissue from CHD and HFD mice, a situation compatible 
with hypothyroidism. The lipase Atgl (patatin-like phospholipase domain-containing protein 2) increased signif-
icantly under  HFD21,47. Other lipases, such as Lipe (hormone-sensitive lipase), decreased in HFD, in agreement 
to their role in controlling  lipolysis47,48, whereas Lpl (lipoprotein lipase) remained unchanged in all conditions 
assayed (Fig. 4b). Among other genes involved in lipid homeostasis, a marked increase in Ppara, but not in 
Pparg was evidenced in the absence of NOD1 (not shown). Because lipid accumulation is evident in eWAT from 
NOD1 KO animals fed HFD, it can be suggested that lipogenesis is markedly enhanced in this tissue through 
mechanisms not yet fully established. Since infiltrating immune cells may influence the physiology of adipo-
cytes, eWAT resident immune cell populations were determined by flow cytometry. As Fig. 4c shows, no signifi-
cant differences in the content of CD45-positive cells or in the tissue distribution of myeloid cells was observed 
under CHD. However, after HFD, the eWAT tissue from NOD1 KO mice exhibited a large infiltration of mac-
rophages, but with lesser neutrophilia (Fig. 4c, lower panel), despite the larger size of the eWAT adipocytes from 
NOD1 KO HFD fed mice. In addition to eWAT, the liver from NOD1 KO mice under HFD presented a signifi-
cant steatosis, without elevation of serum transaminases except for a modest, although statistically significant 
increase in alanine aminotransferase (ALT; Fig. 4d). This increased lipogenesis in the absence of NOD1 under 
HFD was confirmed by the fatty acid composition of livers that showed an increase of polyunsaturated fatty acids 
(PUFA) and a decrease of saturated fatty acids (SFA), a metabolic situation associated with the development of 
non-alcoholic fatty liver disease (NAFLD)49 (Fig. 4e). Interestingly, WT mice fed a HFD for 4 weeks followed by 
2 weeks on CHD fully recovered from the lipid accumulation in liver, whereas NOD1 KO mice under the same 
nutritional protocol still exhibited clear signs of steatosis and lipid accumulation in the liver (Supplementary 
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Figure 1.  NOD1 deficient mice exhibit enhanced body weight and obesity after feeding high-fat diet (HFD). 
12-weeks old WT (n = 27) and NOD1 KO mice (n = 26) maintained in chow diet (CHD) were fed for 6 
additional weeks with CHD or HFD. (a) Body weight and representative images of animals. (b) Adipose tissues 
(brown adipose tissue, BAT; epididymal adipose tissue, eWAT; inguinal adipose tissue, iWAT) and liver weight 
under 6-weeks HFD conditions. (c) Serum lipid profile and non-esterified fatty acids content from these 
animals (n = 7, for each group). Results show the mean ± SEM of the indicated samples. **P < 0.01; ***P < 0.005; 
****P < 0.001 vs. the corresponding condition in WT mice. ns not statistically significant.
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Fig. S3). Indeed, HFD significantly activates NOD1 signaling cascade in WT mice through the phosphorylation 
of RIP2 kinase (Supplementary Fig. S4).
NOD1‑deficiency influences bile acid metabolism, inflammation and intestinal lipids in 
HFD‑fed mice. Bile acids (BA), produced in the liver, stimulate energy expenditure through increases in 
D2 deiodinase in BAT. In addition to this, BA are critically important for balanced lipid metabolism and innate 
 immunity19,50. Thus, we investigated the mRNA levels of relevant genes involved in cholesterol catabolism lead-
ing to BA biosynthesis (Fig. 5a, Supplementary Fig. S5). The key sterol hydrolases Cyp7a1 (also increased in 
NOD1 KO CHD-fed mice) and Cyp27a1 were significantly increased in NOD1 KO HFD fed mice, compatible 
with an increase in BA synthesis in NOD1 KO liver (Fig. 5b), due to the elevated levels of cholesterol under 
these conditions. The hepatic levels of the  Na+/BA-cotransporter Slc10a1 were significantly higher in NOD1 
KO vs. WT mice in CHD regimen, suggesting that the enterohepatic circulation of BA into hepatocytes was 
reduced upon HFD treatment. Regarding Nr1h4, the farnesoid X receptor that counteracts the expression of 
Cyp7a1, avoiding excess of BA synthesis, only a minimal but statistically significant decrease was observed in 
NOD1 KO livers under HFD vs. CHD. Furthermore, in vivo NOD1 activation with iE-DAP induced Cyp7a1 in 
liver as did the HFD, at the time that decreased the transcription of Slc10a1 (Supplementary Fig. S5), suggesting 
the existence of alternative mechanisms independent of NOD1 and responsible for the elevation in the levels 
of both genes under HFD. Moreover, increased serum TNFα levels were observed in NOD1 KO mice fed HFD, 
probably due to the enhanced liver Tnfa expression measured in these animals (Fig. 5c,d). Interestingly enough, 
an increase, although not statistically significant, in the liver resident inflammatory monocytes was observed in 
these animals, that was associated with a statistically significant increase in liver macrophages (Fig. 5e). The lipid 
Figure 2.  Evaluation of animal metabolic profiles. WT (n = 12) and NOD1 KO (n = 12) animals were fed 
standard chow diet (CHD) or high-fat diet (HFD) for 6 weeks. The  O2 and  CO2 exchange (a), the Resting 
Energy Expenditure (REE) (b) were registered as described in the “Materials and methods” section, during the 
daylight and darkness periods (12 h). Results show the mean ± SEM of 6 animals per nutritional condition and 
genetic background. *P < 0.05; **P < 0.01; ***P < 0.005 vs. the corresponding condition in WT mice; #P < 0.05, 
##P < 0.01 vs. the corresponding condition under HFD. ns not statistically significant.
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composition of intestinal mucosa from NOD1 KO mice fed HFD included a higher proportion of saturated fatty 
acids and a lower amount of monounsaturated fatty acids vs. their WT counterparts (Fig. 5f).
Thyroid function is altered in mice lacking NOD1. Since thyroid hormones have an impact on tissue 
homeostasis and lipid  metabolism51–53 as well as in energy  expenditure44, we investigated their levels in WT 
and NOD1 KO mice fed CHD or HFD. The serum levels of T4 and T3 were significantly higher in NOD1 KO 
Figure 3.  NOD1 KO mice fed HFD exhibit improved glucose tolerance. WT and NOD1 KO mice were fed 
CHD or HFD for 6 weeks and, at the end of the period were starved and submitted to a glucose tolerance test. 
Plasma glucose level after i.p. administration of 2 g of glucose per kg body weight (a). Plasma insulin levels from 
these animals were determined 15 min after glucose administration (b). Immunoblot levels of Glut4 and pAkt 
in eWAT (c). Results show the mean ± SEM of 6 animals per nutritional condition and genetic background. 
*P < 0.05; **P < 0.01; ***P < 0.005 vs. the corresponding condition in WT mice. ns not statistically significant. 
Immunoblot corresponds to a representative assay out of four.
8
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:12317  | https://doi.org/10.1038/s41598-020-69295-2
www.nature.com/scientificreports/
Figure 4.  NOD1 KO mice fed HFD exhibit a significant increase in eWAT size, infiltration of immune cells and hepatic 
steatosis. Immunohistochemical analysis of eWAT from WT and NOD1 KO mice fed HFD for 6 weeks, and evaluation of 
adipocyte area and cell density (a). qPCR analysis of eWAT lipases from mice fed CHD or HFD for 6 weeks (b). Infiltration 
of immune cells in eWAT (c). Accumulation of lipids in liver and serum transaminase levels from WT and NOD1 KO 
mice fed HFD (d). Hepatic lipid composition from HFD fed animals determined by 1H magnetic resonance spectrum (1H 
MRS-HRMAS) (e). Results show the mean ± SEM of 4 (b, c) and 6 (a, d, e) animals per nutritional condition and genetic 
background. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001 vs. the corresponding condition in WT mice. #P < 0.05, ##P < 0.01, 
###P < 0.005 vs. the corresponding genetic condition under CHD. Ns not statistically significant. Results were expressed as: SFA: 
saturated fatty acids (FFAA); UFA: Unsaturated FFAA; MUFA: monounsaturated FFAA; PUFA: polyunsaturated FFAA; MCL: 
medium chain length FFAA; NDB: number of double bonds in FFAA; PU/UFA, polyunsaturated/unsaturated fatty acids; 
saturation index (Sat. Index), as the ratio between stearic and oleic acids.
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vs. WT mice under CHD, suggesting increased requirements of T4 and T3 in NOD1 KO mice. However, feed-
ing HFD suppressed the differences between both groups (Fig. 6a). Measurement of free thyroidal T4 and T3 
(thyroid FT4 and FT3 ready to be released to serum) in NOD1 KO mice fed CHD showed a strong decrease as 
compared to the WT, indicating damage in the secretion of T4 and T3 in NOD1 KO mice. However, in HFD, 
the FT4 is higher in the thyroid of NOD1 KO animals compared with WT counterparts (Fig. 6a,b). Due to the 
importance of BAT in regulating thermogenesis and energy balance, thyroid hormones levels were assessed in 
BAT and in liver. We found that T4 concentrations were increased in BAT and liver of NOD1 KO animals fed 
CHD in parallel to plasma T4, but feeding HFD also suppressed this T4 rise. Regarding T3 levels, absence of 
NOD1 resulted in equal or low T3 values than in the WT counterparts in BAT and liver, independently of the 
diet (Fig. 6c,d). However, deficiency in NOD1 results in statistically higher D2 activity in BAT, irrespectively of 
the nutritional regime of the animals (Fig. 6c) and nine- to ten-fold increases in Dio2 mRNA (Supplementary 
Fig. S6a), suggesting high activation of BAT machinery to maintain T3 levels in BAT. Of note, that this occurs 
with a normal or high BAT T4 (low T4 is the main activator of D2 activity), that excludes a role for T4 in the 
D2 activity and Dio2 mRNA increases, pointing to other activators for D2 deiodinase as BA or fatty acids. Ucp1 
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Figure 5.  NOD1 KO mice fed HFD exhibit an enhanced liver pro-inflammatory profile. WT and NOD1 KO 
mice were maintained under CHD or HFD for 6 weeks. The hepatic mRNA levels of genes involved in bile acid 
metabolism were determined (a). Quantification of hepatic bile acids (b). The plasma levels of TNF-α (c) and 
the hepatic mRNA levels of Tnfa (d) were determined. The infiltration of immune cells in liver were determined 
by flowcytometry (e). The lipid composition of the ileum was determined by 1H MR spectroscopy (f.). Results 
show the mean ± SEM of 4 (b–e) and 8 (a, f) animals per nutritional condition and genetic background. 
*P < 0.05; **P < 0.01; ***P < 0.005 vs. the corresponding condition in WT mice. #P < 0.05, ##P < 0.01, ###P < 0.005 vs. 
the corresponding genetic condition under CHD. ns not statistically significant. Results were expressed as: SFA: 
saturated fatty acids (FFAA); UFA: Unsaturated FFAA; MUFA: monounsaturated FFAA; PUFA: polyunsaturated 
FFAA; MCL: medium chain length FFAA; NDB: number of double bonds in FFAA; PU/UFA, polyunsaturated/
unsaturated fatty acids; saturation index (Sat. Index), as the ratio between stearic and oleic acids.
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Figure 6.  Thyroid hormones in plasma, thyroid, BAT and liver; liver D1 and BAT D2 deiodinase activities 
in WT and NOD1 KO mice fed CHD or HFD. Animals were maintained on CHD or fed HFD for 6 weeks. 
The serum (a) and free thyroidal concentrations (b) of T4 T3 were determined. The BAT T4, T3 and T4 type 
2 deiodinase activity (D2 activity) were determined (c). The liver T4, T3 and type 1 deiodinase activity (D1 
activity) were determined (d). Results show the mean ± S.E.M. of 9–15 animals per nutritional condition and 
genetic background. *P < 0.05; **P < 0.01; ***P < 0.005 vs. the corresponding condition in WT mice. #P < 0.05; 
##P < 0.01 vs. the corresponding genetic condition under CHD. ns not statistically significant.
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:12317  | https://doi.org/10.1038/s41598-020-69295-2
www.nature.com/scientificreports/
NOD1 KO mice (Supplementary Fig. S6b). Conversely, D1 activity in liver was significantly lower in NOD1 KO 
animals, which correlates with the T3 levels measured in this tissue (Fig. 6d), despite to observe similar mRNA 
levels for Dio1 (Supplementary Fig. S6c).
Gut microbiota differences in WT and NOD1 KO mice under different diets. Analyses of the 
intestinal microbiota were performed in the two experimental groups (NOD1 KO and WT mice) under the 
CHD and after switching to a HFD. These enabled us to identify differences in microbiota related to both the diet 
(HFD vs. CHD) and the genotype (NOD1 KO vs. WT). In general, indices of α diversity tended to be reduced by 
the HFD but the differences varied depending on the genotype (Fig. 7a). As shown in Fig. 7a, the HFD feeding 
caused decreases in observed OTUs and in the Chao1 index (a measure of species richness) in NOD1 KO mice 
but not in WT mice, suggesting that HFD exerted stronger adverse effects in the gut microbiota composition 
Figure 7.  Characterization of the gut microbiota. (a) Alpha diversity indices (Shannon’s diversity index, Chao1, 
Observed OTUs) from each diet and genotype treatment group. (b) Principle coordinates analysis (PCoA) plot 
using generalized UniFrac distances comparing microbial communities from each treatment group. Group 
means are indicated by the center of each ellipse. Distance-based non-parametric PERMANOVA tests were 
conducted as pairwise comparisons of treatment groups. P values of all pairwise comparisons were corrected for 
multiple comparisons using false discovery rate.
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of the NOD1 KO. Nonetheless, Shannon’s diversity index (species diversity) was slightly lower in WT than in 
NOD1 KO under HFD (Fig. 7a). Comparison of β diversity showed that after a HFD, it appears that the micro-
biota composition changed for both genotype groups when compared to CHD. Analysis using generalized Uni-
Frac (which down-weights abundant or rare taxonomic groups) revealed significant differences between CHD 
and HFD for WT and NOD1 KO groups, individually. However, no significant differences in β diversity could be 
attributed to the genotype, when comparing WT vs NOD1 KO groups for CHD and HFD, respectively (Fig. 7b). 
When differences in specific taxonomic categories were analyzed as a function of the genotype under each spe-
cific dietary period, it was observed that the NOD1 KO group was characterized by lower abundances of the 
family S24-7, as well as the genera Bacteroides and Mucispirillum compared to the WT group under a standard 
CHD (Supplementary Fig. S7). In contrast, higher abundances of the genera Oscillospira, Prevotella, [Prevotella], 
Parabacteroides, AF12 (family Rikenellaceae), Rikenella, Dehalobacterium, Helicobacter, Desulfovibrio and rc4_4 
(family Peptococcaceae) were observed in the NOD1 KO group compared to the WT under a CHD. After HFD 
feeding, the NOD1 KO group was characterized by higher abundances of the family Desulfovibrioaceae and 
the genera Odoribacter, Prevotella, Parabacteroides, [Ruminococcus], Rikenella, Paraprevotella and Helicobacter 
compared to the WT group. Therefore, four bacterial groups were increased in NOD1 KO mice compared to WT 
regardless of the diet, including Prevotella, Parabacteroides, Rikenella and Helicobacter. The HFD feeding caused 
a decrease in several genera (Bifidobacterium, Rikenella, Bilophila, rc4_4 and Enterococcus) and an increase in 
others (Helicobacter) in both WT and NOD1 KO groups, compared to the groups fed the CHD, revealing the 
key influence of the diet on the gut microbiota composition above the genetic background. Of these bacterial 
groups, the initial increased levels of Helicobacter found in NOD1 KO mice could aggravate the effects of the 
HFD, which also could contribute to their increase. Specific effects of the HFD depending on the genotype were 
also detected. Indeed, the HFD decreased the abundance of some taxonomic genera (Oscillospira, Coprococcus 
and Streptococcus) only in the NOD1 KO group. Other taxonomic genera were increased only in the NOD1 KO 
group (Bacteroides, [Ruminococcus], Dorea) or the WT group (Desulfovibrio, Allobaculum) under HFD feeding. 
These findings suggest that the genotype influences the susceptibility of the host to diet-induced microbiota 
changes (Supplementary Fig. S7).
Discussion
In this work, we show that under a standard CHD, the absence of NOD1 does not alter lipid metabolism nor 
promote obesity, as deduced by the presence of normal adipose tissue and complete absence of liver steatosis in 
these mice. However, HFD favors a rapid and significant development of obesity, or at least overweight, caused 
by an enlargement of eWAT adipocytes and enhanced hepatic steatosis in NOD1 KO mice, whereas this situa-
tion is delayed in the WT counterparts. Blood lipids from NOD1 KO mice fed HFD show an increase in total 
cholesterol, mainly due to the elevation of the HDL fraction. When animals are analyzed in metabolic cages, 
the absence of NOD1 results in higher REE values. However, under a HFD regimen, the rise in REE during the 
darkness period is lesser than in the WT animals, contributing to the increased obesity in NOD1 KO mice vs. 
the same genotype in CHD. Indeed, the significant decreased levels of Pnpla3 in eWAT suggest a moderate hypo-
thyroidism, as previously  described35. In fact, among the targets responsive to thyroid hormones and involved 
in obesity, Pnpla3 plays a role in the enlargement of eWAT 35. However, the situation is more complex in view of 
the elevation of Atgl levels, a key enzyme in triglyceride  lipolysis47, in the absence of NOD1, both under CHD 
and HFD vs. the corresponding levels in the WT counterparts.
We provide evidence of different mechanisms that could explain this accelerated obesity of NOD1 KO mice 
fed HFD. According to our data, one of the key players is a significant alteration of thyroid hormone homeo-
stasis at 6 weeks after HFD. Under a CHD, NOD1 deficiency results in higher serum levels of both T3 and T4, 
accompanied by lower FT4 and FT3 hormones in the thyroid (hormone ready to be released). Thyroidal FT4 
and FT3 are strongly decreased in NOD1 KO mice fed CHD, showing a profound effect of thyroid secretion. If 
similar decreases in NOD1 expression or activity were found in humans, with decreases in thyroidal FT4 and 
FT3, this would indicate the early involvement of the thyroid in pathological events, such as obesity associated 
to alterations in this NLR. This thyroid situation is reversed under HFD, which may contribute to the increased 
obesity of NOD1 deficient mice. The strong response of BAT D2 deiodinase points to higher T3 requirements 
in NOD1 KO mice. Regarding other alternatives accounting for T3 decreased levels, such as Dio3, it should 
be mentioned that Dio3 is expressed mainly during fetal life and in proliferative situations, including cells in 
culture. Dio3 is the main pathway for T3 degradation. It has been reported that Dio3 is not expressed or it is 
undetectable in murine BAT, thyroid and adult liver. Therefore, thyroid hormone dysfunction appears to be an 
early event prior to the development of insulin resistance, and related to the gain in body weight mainly through 
lipid accumulation in fat and liver tissues.
It is known that HFD alters the permeability of the intestinal barrier, and its integrity is compromised by this 
dietary  regimen24,25,54–56. HFD lipids, in combination with bacterial molecules from the gut microbiota (bacterial 
cell wall components, DNA, etc.) are translocated across this barrier and gain access to systemic circulation and 
activate pro-inflammatory pathways, not only in immune cells but also in other tissues where NOD1 and NOD2 
are  expressed11,12,50. Our data suggest that HFD is involved in the rise of circulating NOD1 activatos as deduced 
by the increase in the phosphorylation of the adaptor RIPK2 in the WT mice. Interestingly, the absence of NOD1 
per se has an impact on the gut microbiota composition, which exhibits a higher content in Parabacteroides, 
Prevotella, Rikenella and Helicobacter regardless of the diet. The differences in microbiota related to the NOD1 
deletion seem to influence the subsequent HFD-induced effects on the gut ecosystem, which could contribute 
to aggravate the immune-metabolic phenotype of the obese mice. In addition to this, NOD1 deficiency in epi-
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Exacerbation of the adverse metabolic effects of the HFD in NOD1 KO mice compared to WT mice, including 
increased adiposity and lipogenesis and changes in ileum lipid composition could be related to dietary-induced 
alterations in the natural intestinal ecosystem of the NOD1 KO animals. This is characterized by reductions in 
some diversity indexes and shifts in the abundance of specific bacterial taxonomic groups. A role for dietary-
induced changes in the microbiota in dietary lipid absorption and deposition in peripheral tissues has been 
reported in different study  models12,57. Diet-induced increases in the phylum Firmicutes were shown to increased 
lipid absorption in the intestine through fecal transplantation  experiments57. Other studies reported that that 
lipid absorption could be increased by a microbiota enriched in Clostridiaceae and with reduced abundance of 
Bacteroidaceae and Bifidobacteriaceae12. In our study, HFD-induced reductions in Bifidobacterium, which could 
explain increased lipid absorption leading to obesity and adiposity, although these effects were identified in both 
WT and NOD1 KO and attributed exclusively to the HFD. Specific dietary effects on the intestinal ecosystem of 
NOD1 KO mice (not detected in WT mice under HF feeding), such as reductions in Oscillospira, Coprococcus 
or Streptococcus and increases in others (Dorea, [Ruminococcus] or Bacteroides) could account for the stronger 
adverse impact of the diet on lipid absorption and metabolism than in WT mice. Oscillospira has often been 
associated with leanness in human microbiota  studies58, although opposite associations have also been reported 
in WT  rodents59. This potential benefits could be attributed to the ability of Oscillospira spp. to produce butyrate, 
which is thought to play positive roles in  obesity58. Oscillospira spp. also utilize as a primary energy source host-
derived glycans (glucoronate), instead of dietary starches, which will cost energy to the host and could explain 
its positive association with leanness in  humans58. By contrast, increases in Dorea have been positively associated 
with obesity/adiposity in  rodent59,60 and  human61 studies.
Specific taxa of the gut microbiota regulate proteins involved in BA metabolism, such as BA transporters, 
bile salt hydrolase (BSH) and BA 7α-dehydroxylase activities. These are responsible for both BA deconjugation 
and subsequent dehydroxylation in the distal gut. Their activity could increase the excretion of BAs in feces and 
reduce their concentrations in the body, leading to induction of BA synthesis from cholesterol in the  liver11,12. 
Therefore, the induction of the expression of Cyp7a1 in the liver of NOD1 KO mice under both the CHD and 
the HFD could be related to the specific microbiota alterations associated with the mouse genotype and the 
subsequent effect of the HFD. For example, Parabacteroides spp., which showed higher abundances in NOD1 
KO mice, although were not specifically increased by the HFD, produce secondary BAs and, thereby, could 
contribute to inducing BA synthesis from cholesterol in the liver as  well62–64.
Collectively, the low-grade immune response upon HFD is exacerbated in the case of NOD1 deficiency, 
contributing to dysfunctional lipid synthesis, due to a higher infiltration of pro-inflammatory immune cells in 
adipose and liver  tissues18,20, as confirmed by the quantification of the infiltrated cells and the rise in circulating 
TNF-α levels. Indeed, experiments using germ-free mice show protection against HFD-induced obesity in NOD1 
KO animals, although this phenotype is suppressed when mice are housed under conventional conditions and the 
gut becomes  colonized13,18,65–67. The HFD used promoted a modest increase in body weight of the WT animals 
(9.8% increase after 6 weeks); however, in the absence of NOD1 the body weight gain was 33.3% during this 
period, reflecting this obesity in adipose tissue and in the liver. In addition to this, these tissues became more infil-
trated by immune cells, such as macrophages and neutrophils, as it has been previously  described4,22,24. The idea 
that lipids and bacterial-derived molecules cooperate in the induction of ‘metabolic inflammation’ and obesity 
comes from the fact that particularly NOD1 is overexpressed and activated in adipose tissue in response to these 
 challenges10,18,20,23. However, our data provide a different scenario since constitutive deficiency of NOD1 worsens 
the metabolic dysfunction due to HFD. In fact, NOD1 polymorphisms in humans -associated with differences in 
the activity of this NLR- appear to play a relevant role in inflammatory-related diseases, including  obesity23,68,69.
Regarding insulin resistance and NLR activity, other groups have described that NOD1 activation after iE-DAP 
administration promotes insulin  resistance20,23,24,70. However, in animals lacking NOD1 in the hematopoietic system, 
Chan et al.18 reported that after 18 weeks of HFD, the WT animals exhibited hyperinsulinemia, insulin resistance and 
a reduced capacity to decrease glucose overload, a situation that was significantly more benign in the hematopoietic 
NOD1 deficient mice. Here we provide a new piece of knowledge since our animals deficient in NOD1 and fed a 
HFD for 6 weeks, despite an evident obesity, are not resistant to insulin and exhibit an improved glucose tolerance test 
when compared with the WT counterparts. These results suggest that additional dysfunctional changes are required 
to establish insulin resistance and defective oral glucose tolerance test, compatible with diabetes progression in WT 
animals. Moreover, reversion to CHD after 6 weeks of HFD shows a significant recovery in the liver steatosis of the 
NOD1 KO animals and almost complete absence of Oil-red O staining in the WT counterparts, which is in agree-
ment with the failure of the establishment of the insulin-resistance phenotype in these 6 weeks of HFD regimen.
Finally, although less attention has been paid to thyroid metabolism associated with microbial composition it 
remains a relevant pathophysiological issue as observed from our results in the NOD1 KO mice, and discussed in 
a recent  review71. Indeed, our data suggest an interplay between NOD1 activity, microbiota and thyroid hormone 
function that might help to unravel unexpected obesity-related pathologies in humans.
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